Mosquitoes that landed on surfaces coated with the antimalarial compound atovaquone were completely blocked from developing Plasmodium falciparum (P. falciparum), the parasite that causes malaria, according to new research led by Harvard T.H. Chan School of Public Health.
The study showed that atovaquone—an active ingredient in medication that’s commonly used in humans to prevent and treat malaria—can be absorbed through mosquitoes’ tarsi (legs) and prevents the insects from developing and spreading the parasite. The findings indicate that treating bed nets with atovaquone or similar compounds would be an effective way to reduce the burden of malaria while significantly mitigating the growing problem of insecticide resistance.
“Mosquitoes are amazingly resilient organisms that have developed resistance against every insecticide that has been used to kill them. By eliminating malaria parasites within the mosquito rather than killing the mosquito itself, we can circumvent this resistance and effectively prevent malaria transmission,” said Flaminia Catteruccia, professor of immunology and infectious diseases. “Ultimately, the use of antimalarials on mosquito nets could help eliminate this devastating disease. It’s a simple but innovative idea that’s safe for people who use mosquito nets and friendly to the environment.”
The study was published online in Nature on February 27, 2019.
Malaria poses a risk to nearly half of the world’s population. Annually, more than 200 million people become sick with malaria and more than 400,000 people die from it. During the past 20 years, bed nets treated with long-lasting insecticides that kill mosquitoes have significantly reduced the global malaria burden. It’s estimated that such bed nets are responsible for 68% of all malaria cases averted since 2000. Recent years, however, have seen a surge in mosquitoes that are resistant to the most commonly used insecticides. In some malaria hot spots, there is near total resistance to pyrethroids, one of the key groups of insecticides currently in use. The waning effectiveness of insecticides is a public health emergency that threatens to undo decades of progress toward controlling malaria and highlights the urgent need to develop new approaches to stop the spread of the disease.
For this study, the researchers reasoned that they could introduce antimalarial compounds to Anopheles mosquitoes in a way that’s similar to a mosquito making contact with insecticides on a bed net. Rather than kill the mosquitoes, the aim was to give them a prophylactic treatment so that they could not develop and transmit the malaria-causing parasite.
To test the approach, they coated glass surfaces with atovaquone and covered them with a plastic cup. Female mosquitoes were then introduced into the cup. Prior to or immediately after the mosquitoes made contact with the atovaquone-coated glass, the researchers infected them with P. falciparum. Over the course of the study, mosquitoes were exposed to different concentrations of atovaquone and were kept in the cups for different amount of times.
The study found that P. falciparum development was completely blocked at relatively low concentrations of atovaquone (100 ?mol per m2) and when mosquitoes were exposed for just 6 minutes, which is comparable to the time wild mosquitoes spend on insecticide-treated bed nets. The researchers had similar success when using other compounds similar to atovaquone. While atovaquone effectively killed parasites, it had no effects on mosquito lifespan or reproduction.
“When we put these data into a mathematical model using real-world data on insecticide resistance, bed net coverage and malaria prevalence, it showed that supplementing conventional bed nets with a compound like atovaquone could appreciably reduce malaria transmission under almost any conditions we had data for in Africa,” said Douglas Paton, research fellow and lead author of the paper. “What got us really excited is that it also showed that this new intervention would have the greatest impact in areas with the highest levels of mosquito insecticide resistance.”
Learn more: Applying antimalarial drugs to bed nets could lead to drop in malaria transmission
The Latest on: Atovaquone
[google_news title=”” keyword=”atovaquone” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Atovaquone
- 60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseaseson May 8, 2024 at 4:59 am
The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness.The upcoming 60 Degrees Pharma clinical trial of ...
- Long-Term Malaria Prophylaxis for Travelerson May 7, 2024 at 5:00 pm
Priority should be given to drugs that may be used for both chemoprophylaxis and standby, such as mefloquine and atovaquone-proguanil. Expatriates who live where malaria is hyper- or holoendemic ...
- Malaria Newson May 6, 2024 at 4:59 pm
Potential for Injectable 'Chemical Vaccine' for Malaria Using Atovaquone Oct. 20, 2023 — Researchers looking to develop a long-acting, injectable malaria preventive using atovaquone have shown ...
- Product Recalls: All Warnings Issued in April 2024on May 1, 2024 at 8:36 am
The U.S. Food and Drug Administration ( FDA) recalled 28 products in April 2024, ranging from foods to supplements to animal feed. The FDA regularly tests and reviews products to ensure they meet ...
- Food Recall List: Every Product Removed This Monthon April 30, 2024 at 8:22 am
The U.S. Food and Drug Administration ( FDA) and the Food Safety and Inspection Service (FSIS) announced the recalls on food products ranging from ice cream to cheese and bread. Recalls were also ...
- Malaria: Still a Global Health Problemon April 13, 2024 at 5:00 pm
Briefly, the CDC recommends that travelers to malaria-risk areas of South America, Africa, the Indian subcontinent, and the South Pacific take either mefloquine or doxycycline or atovaquone and ...
- Testing found this recalled medicine can have a deadly bacterial contaminationon April 3, 2024 at 10:22 am
AvKARE recalled one lot of Atovaquone Oral Suspension after third-party testing discovered a potential Bacillus cereus contamination in the medicine. As for what that means, the risk statement in ...
- AvKARE, LLC. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750 mg/5 mL Due to Potential Bacillus Cereus Contaminationon March 31, 2024 at 9:00 pm
AvKARE, LLC. is voluntarily recalling lot # AW0221A of Atovaquone Oral Suspension, USP 750mg/5mL to the Consumer/User level, due to the potential Bacillus cereus contamination in the product found ...
- Page settingson January 15, 2024 at 2:40 pm
This medication contains 2 medicines: atovaquone and proguanil. It is used to prevent and treat malaria caused by mosquito bites in countries where malaria is common. Malaria parasites can enter ...
- Growing Cases Of Malaria In The U.S. Prompt CDC Alerton June 27, 2023 at 6:44 am
For treatment, “Artemether-lumefantrine (Coartem®) is the preferred option;” Atovaquone-proguanil (Malarone®) is also recommended. If these are not available, patients should be transferred ...
via Bing News